WO2008072532A1 - 貯蔵安定性が改善された医薬組成物 - Google Patents
貯蔵安定性が改善された医薬組成物 Download PDFInfo
- Publication number
- WO2008072532A1 WO2008072532A1 PCT/JP2007/073548 JP2007073548W WO2008072532A1 WO 2008072532 A1 WO2008072532 A1 WO 2008072532A1 JP 2007073548 W JP2007073548 W JP 2007073548W WO 2008072532 A1 WO2008072532 A1 WO 2008072532A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- water
- compound
- pharmacologically acceptable
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Definitions
- the present invention provides:
- (B) It relates to a pharmaceutical composition containing a water-soluble polymer and excellent in storage stability.
- Patent Document 1 The compound having the above general formula (I) or a pharmacologically acceptable salt thereof is known as a compound having an inhibitory action on platelet aggregation (Patent Document 1 or 2).
- Patent Documents 2, 3, 4, 5, and 6 exemplify many additives that can be used in the preparation of the compound having the above general formula (I) or a pharmacologically acceptable salt thereof.
- hydroxypropinoresenorelose, hydroxypropinoremethinorescenellose, polyvinylenopyrrolidone and / or polyethylene glycol are listed in one line S, as one of many usable additives It is only exemplified and not specifically used in formulation examples.
- the above patent document discloses that the storage stability is improved by including a water-soluble polymer in a pharmaceutical composition containing the compound having the above general formula (I) or a pharmacologically acceptable salt thereof. Neither listed nor suggested.
- Patent Document 1 JP-A-6-41139
- Patent Document 2 Japanese Patent Laid-Open No. 2002-145883
- Patent Document 3 JP-A-10-310586
- Patent Document 4 Japanese Patent Laid-Open No. 2003-246735
- Patent Document 5 Japanese Unexamined Patent Application Publication No. 2004-51639
- Patent Document 6 International Publication No. 2004/098713 Pamphlet
- An object of the present invention is to provide a pharmaceutical composition excellent in storage stability, containing a compound having the above general formula (I) or a pharmacologically acceptable salt thereof.
- the present inventors have found that the compound having the above general formula (I) or a pharmacologically acceptable salt thereof contains a water-soluble polymer.
- the present inventors have found that a pharmaceutical composition containing the compound has excellent storage stability, and have completed the present invention.
- the present invention provides (A) a compound having the above general formula (I) or a pharmacologically acceptable salt thereof and
- a pharmaceutical composition (especially a composition for the prevention or treatment of thrombosis or embolism) characterized by containing a water-soluble polymer;
- a compound having the above general formula (I) or a pharmacologically acceptable salt thereof for the manufacture of a composition for prevention or treatment a compound having the above general formula (I) or a pharmacologically acceptable
- the present invention provides:
- the pharmaceutical composition according to (1) which is loose or polybulurpyrrolidone,
- composition according to any one of (1) to (4), wherein the blending amount of the water-soluble polymer is 1.0 to 40% by weight with respect to the total amount of the pharmaceutical composition.
- composition according to any one of (1) to (4), in which the blending amount of the water-soluble polymer is 2.5 to 20.0% by weight relative to the total amount of the pharmaceutical composition.
- composition according to any one of (1) to (6) which is a compound having:
- composition according to any one of (1) to (7), wherein the pharmaceutical composition is a powder, fine granules, granules, capsules or tablets, or
- a pharmaceutical composition excellent in storage stability comprising (A) a compound having the above general formula (I) or a pharmacologically acceptable salt thereof and (B) a water-soluble polymer. It can be provided.
- the pharmaceutical composition of the present invention is, for example, a therapeutic and / or prophylactic agent for thrombosis or embolism (preferably thrombosis) (preferably a thrombosis therapeutic agent and / or prophylactic agent). Effective).
- the "pharmacologically acceptable salt” of the present invention includes, for example, a hydrohalide such as hydrofluoride, hydrochloride, hydrobromide or hydroiodide; nitrate , Perchloric acid Inorganic acid salts such as salts, sulfates or phosphates; lower alkyl sulfonates such as methane sulfonate, trifluoromethane sulfonate or ethane sulfonate; benzene sulfonate or p-toluene sulfonate Organic acid salts such as acetate, malate, fumarate, succinate, succinate, ascorbate, tartrate, succinate or maleate; Alternatively, glycine salt, lysine salt, arginine salt, ornithine salt, amino acid salt such as glutamate or aspartate, and the like can be mentioned. More preferred are hydrochlorides or maleates, and most preferred are hydrochlorides
- the "water-soluble polymer" of the present invention includes, for example, cellulose derivatives such as hydroxypropylmethylcellulose, sodium and the like; polybulur pyrrolidone, aminoalkyl methacrylate copolymer, carboxybule polymer, polybulal alcohol or polyethylene.
- Synthetic polymers such as Nglycol; HA “Sankyo” (manufactured by Sankyo Co., Ltd.); gum arabic; agar; gelatin; or sodium alginate, and preferably hydroxypropylmethylcellulose, hydroxypropyl Cellulose or polybulur pyrrolidone is loose, and most preferably hydroxypropylcellulose.
- the above water-soluble polymer can be used alone or in combination of two or more.
- the pharmaceutical composition of the present invention may further comprise an appropriate pharmacologically acceptable excipient, lubricant, binder, emulsifier, stabilizer, flavoring agent and / or diluent as necessary. It is possible to include additives such as S.
- excipient examples include sugar derivatives such as lactose, sucrose, glucose, mannitol or sorbitol; starch derivatives such as corn starch, potato starch, ⁇ -denpone or dextrin; Cellulose derivatives such as cellulose; gum arabic; dextran; or organic excipients such as pullulan: or silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, calcium silicate or magnesium metasilicate aluminate; phosphoric acid Phosphates like calcium hydrogen; of calcium carbonate
- An inorganic excipient such as a sulfate such as calcium sulfate, and preferably one or more excipients selected from cellulose derivatives and sugar derivatives, More preferred is one or more excipients selected from lactose, mannitol and crystalline cellulose, most preferred is lactose and / or crystalline cellulose.
- Examples of the “lubricant” used include stearic acid; stearic acid metal salts such as calcium stearate or magnesium stearate; talc; colloidal silica; waxes such as bead wax or gale.
- sulfate such as sodium sulfate, glycol, fumaric acid, sodium stearyl fumarate, sucrose fatty acid ester, sodium benzoate, D, L-leucine, sodium lauryl sulfate or magnesium lauryl sulfate
- Lauryl sulfates such as: silicic acids such as silicic anhydride or silicic acid hydrates; or the starch derivatives mentioned above, preferably metal stearates.
- binder examples include the same compounds as the excipients.
- Emulsifiers used include, for example, colloidal clays such as bentonite or bee gum; metal hydroxides such as magnesium hydroxide or aluminum hydroxide; shades such as sodium lauryl sulfate or calcium stearate. Ionic surfactants; cationic surfactants such as benzalkonium chloride; or nonionic surfactants such as polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters or sucrose fatty acid esters .
- Examples of the "stabilizer” used include para-benzoic acid esters such as methylparaben or propylparaben; alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol; benzalkonium chloride; And phenols such as thiol or talesol; thimerosal; dehydroacetic acid; or sorbic acid.
- sweeteners such as sodium saccharin or aspartame
- acidulants such as citrate, malic acid or tartaric acid
- menthol lemon or orange. And the like.
- the compound having the above general formula (I) or the pharmacologically acceptable amount thereof in the total amount of the pharmaceutical composition is not particularly limited, but for example, it may be 1.0 to 30.0% by weight (preferably 1.3 to 20.0% by weight) based on the total weight of the pharmaceutical composition. preferable.
- the amount of the additive in the total amount of the pharmaceutical composition is not particularly limited.
- the water-soluble polymer is added in an amount of 1.0 to 40% by weight (based on the total weight of the pharmaceutical composition). (Preferably 2.5 to 20.0% by weight), excipient 10.0-93.5% by weight (preferably 44.0-90.0% by weight), and lubricant 0. 5 to 5.0% by weight (preferably 0.5 to 3.0% by weight), 0.0-15.0% by weight of binder (preferably 2.5 to; 10.0% by weight) ) Is preferably blended.
- the pharmaceutical composition of the present invention is preferably a solid preparation, for example, a tablet (including a sublingual tablet and an orally disintegrating agent), a capsule (including a soft capsule and a microcapsule), a granule, Fine granules, powders, pills, chews or lozenges can be mentioned, and preferred are powders, fine granules, granules, capsules or tablets, and most preferred are tablets.
- a method for producing the preparation in the present invention a general method described in a publication such as Power Technology and Pharmaceutical Process (D. Cmilia et al., Elservier Science Pub Co (December 1, 1993)).
- a dry production method for example, a dry granulation method or a direct tableting method, preferably a direct tableting method is preferable.
- the "direct tableting method” is a method of preparing a raw material powder by direct compression molding.
- the "dry granulation method” is a method in which a raw material powder is compression-molded into a slug or a sheet and crushed and divided by an appropriate method to prepare a formulation. These methods are the Theory and Practice of Industrial Pharmacy (Third Edition) (Leon Lachman et al .: LEA & FEBIGER 1986) or Pharmaceutical Dosage Forms: Tablets volume 1 (Second Edition) (Herbert A. Lieberman et al .: MARCEL DEKKER INC. 1989 ).
- the granulation refers to an operation for producing granules having a substantially uniform shape and size from raw materials such as powder, lump, solution or molten liquid. The final granule, powder, fine granule, etc. There are granulations that produce products and granulations that produce intermediate products such as tablets or capsules.
- the compression molding process is a process of applying pressure to the raw material powder with a mechanical force to turn the raw material powder into a lump.
- the apparatus used in the process include dry tablets such as a rotary tablet machine (manufactured by Kikusui Seisakusho Co., Ltd., Hata Iron Works Co., Ltd., Sakakibara Seiki Co., Ltd., etc.)
- dry tablets such as a rotary tablet machine
- examples thereof include granulators (manufactured by Freund Sangyo Co., Ltd., Turbo Kogyo Co., Ltd., Kurimoto Kyosho Co., Ltd., Matsubo Co., Ltd., Nippon Danurator Co., Ltd., Fuji Powdere Co., Ltd.).
- the crushing / splitting process is a process of crushing the lump formed in the compression molding process to an appropriate size with a knife / cutter, etc.
- equipment used include a power mill, a fit mill, and a fiore.
- crushing machines such as Comil or granulators (Fuji Baudal, Deoksugaku Kogyo, Baurek, etc.) can be cited.
- the granulated product thus obtained is sized to a desired particle size, and can be made into a preparation in the form of a powder, fine granule or granule. These preparations can be filled into capsules to form capsules, or further, disintegrating agents and / or lubricants can be added as necessary, and compressed into tablets using a tableting machine. It can also be. Operations such as mixing or granulation are all widely used in the field of pharmaceutical technology, and those skilled in the art can appropriately perform them.
- the tablet may be provided with at least one film coating.
- Coating is performed using, for example, a film coating apparatus.
- the film coating base include sugar coating base, water-soluble film coating base, enteric film coating base, and sustained-release film. Coating bases can be mentioned
- sucrose is used, and one or more selected from talc, precipitated calcium carbonate, phosphate, calcium sulfate, gelatin, gum arabic, polybulurpyrrolidone, pullulan and the like. Can also be used in combination.
- Examples of the water-soluble film coating base include hydroxypropyl cellulose, hydroxypropinoremethinoresenorelose, hydroxyethinoresenorelose, methinorehydroxyconductor; polybulacetal jetylaminoacetate, amino Mention may be made of synthetic polymers such as alkyl methacrylate copolymers or polybulurpyrrolidone; or polysaccharides such as pullulan.
- Examples of enteric film coating bases include cellulose derivatives such as hydroxypropinoremethinorescenole mouth phthalate, hydroxypropinoremethinoresenorelose acetate succinate, canoleboxymethylethyl cellulose or cellulose acetate phthalate. Body; acrylic acid derivatives such as (meth) acrylic acid copolymer L, (meth) acrylic acid copolymer LD or (meth) acrylic acid copolymer S; or natural products such as shellac.
- the sustained-release film coating base includes, for example, cellulose derivatives such as ethyl cellulose; or aminoalkyl methacrylate copolymer RS or ethyl acrylate 'methyl methacrylate copolymer emulsion. And acrylic acid derivatives.
- Two or more of the above coating bases may be mixed and used at an appropriate ratio. Further, if necessary, additives such as appropriate pharmacologically acceptable plasticizers, excipients, lubricants, masking agents, coloring agents and / or preservatives can be contained.
- plasticizer that can be used in the present invention is not particularly limited and can be appropriately selected by those skilled in the art.
- plasticizers include propylene glycol, polyethylene glycol, polypropylene glycol, glycerin and sorbitol, glycerin triacetate, jetyl phthalate and triethyl taenoate, lauric acid, sucrose, dextrose, sorbitol, triacetin, and acetyl.
- examples thereof include triethyl citrate, triethyl citrate, tributyl citrate, and acetyl tilpyl citrate.
- Examples of the concealing agent that can be used in the present invention include titanium oxide.
- Examples of the colorant that can be used in the present invention include titanium oxide, iron oxide, ferric oxide, yellow ferric oxide, and yellow No. 5 aluminum lake talc.
- preservatives examples include noraben and the like.
- the dose of the compound having the above general formula (I) or a pharmacologically acceptable salt thereof, which is an active ingredient of the pharmaceutical composition of the present invention is a species such as drug activity, patient symptom, age or weight. It can change according to various conditions. In the case of oral administration, each dose is usually 1 day for adults, with a lower limit of 0. Olmg (preferably lmg) and an upper limit of 200 mg (preferably lOOmg). Can be administered.
- the obtained mixed powder was tableted with a rotary tableting machine at a tableting pressure of 5.9 kN so that the tablet mass was about 80 mg.
- the obtained uncoated tablets were spray-coated with a coating solution consisting of hydroxypropylmethylcellulose, lactose, titanium oxide, triacetin and water in a pan coating machine to obtain tablets containing test compounds.
- the stability test was done about the obtained tablet. Table 1 shows the test results.
- the obtained mixed powder was tableted with a rotary tableting machine so that the tablet mass was about 80 mg. Tableting was performed at a pressure of 5.9 kN.
- the obtained uncoated tablets were spray-coated with a coating solution consisting of hydroxypropylmethylcellulose, lactose, titanium oxide, triacetin and water in a pan coating machine to obtain tablets containing the test compound. The stability test was done about the obtained tablet. Table 1 shows the test results.
- Compound A (3.4 g), polybulurpyrrolidone (17.5 g), cross-linked sodium carboxymethyl cellulose (12.5 g) and lactose (215.3 g) were mixed for 3 minutes with a high-speed stirring mixer, and then magnesium stearate. (1.3 g) was added and mixed again with a high-speed stirring mixer to obtain a mixed powder.
- the obtained mixed powder was tableted with a rotary tableting machine at a tableting pressure of 5.9 kN so that the tablet mass was about 80 mg.
- the obtained uncoated tablets were spray-coated with a coating solution consisting of hydroxypropylmethylcellulose, lactose, titanium oxide, triacetin and water in a pan coating machine to obtain tablets containing test compounds.
- the stability test was done about the obtained tablet. Table 1 shows the test results.
- the obtained mixed powder was tableted with a rotary tableting machine at a tableting pressure of 5.9 kN so that the tablet mass was about 80 mg.
- the obtained uncoated tablets were spray-coated with a coating solution consisting of hydroxypropylmethylcellulose, lactose, titanium oxide, triacetin and water in a pan coating machine to obtain tablets containing test compounds.
- the stability test was done about the obtained tablet. Table 1 shows the test results.
- the tablets obtained in Examples 1 to 3 and the tablet obtained in Comparative Example 1 are placed in a brown glass bottle and left to stand in a sealed state at 60 ° C. After 3 weeks, the active ingredients in the test tablets (general formula The content of (compound having (I)) was measured by high performance liquid chromatography.
- a pharmaceutical composition excellent in storage stability containing the compound having the above general formula (I) or a pharmacologically acceptable salt thereof and a water-soluble polymer can be obtained.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07850164A EP2100607A4 (en) | 2006-12-07 | 2007-12-06 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED STORAGE STABILITY |
CA2672154A CA2672154C (en) | 2006-12-07 | 2007-12-06 | Pharmaceutical composition having improved storage stability |
US12/312,966 US20100280064A1 (en) | 2006-12-07 | 2007-12-06 | Pharmaceutical composition having improved storage stability |
JP2008549265A JPWO2008072532A1 (ja) | 2006-12-07 | 2007-12-06 | 貯蔵安定性が改善された医薬組成物 |
CN2007800449061A CN101600431B (zh) | 2006-12-07 | 2007-12-06 | 具有改进贮存稳定性的药物组合物 |
BRPI0719398 BRPI0719398A2 (pt) | 2006-12-07 | 2007-12-06 | Composição farmacêutica. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006330372 | 2006-12-07 | ||
JP2006-330372 | 2006-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008072532A1 true WO2008072532A1 (ja) | 2008-06-19 |
Family
ID=39511552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/073548 WO2008072532A1 (ja) | 2006-12-07 | 2007-12-06 | 貯蔵安定性が改善された医薬組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20100280064A1 (ja) |
EP (1) | EP2100607A4 (ja) |
JP (1) | JPWO2008072532A1 (ja) |
KR (1) | KR101647842B1 (ja) |
CN (1) | CN101600431B (ja) |
BR (1) | BRPI0719398A2 (ja) |
CA (1) | CA2672154C (ja) |
TW (1) | TWI488657B (ja) |
WO (1) | WO2008072532A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009036646A1 (de) | 2009-08-07 | 2011-02-10 | Ratiopharm Gmbh | Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon |
WO2011052499A1 (ja) * | 2009-10-28 | 2011-05-05 | 第一三共株式会社 | 貯蔵安定性が改善された医薬組成物 |
WO2011052500A1 (ja) * | 2009-10-28 | 2011-05-05 | 第一三共株式会社 | ワックス安定製剤 |
WO2011098536A1 (en) | 2010-02-11 | 2011-08-18 | Ratiopharm Gmbh | Prasugrel in micronized, crystalline form and pharmaceutical composition thereof |
EP2377520A1 (de) | 2010-03-24 | 2011-10-19 | Ratiopharm GmbH | Pharmazeutische Zusammensetzung des Prasugrels |
WO2013024663A1 (ja) * | 2011-08-12 | 2013-02-21 | 三菱瓦斯化学株式会社 | 保存安定性に優れたs-アデノシル-l-メチオニン含有組成物 |
US9034860B2 (en) | 2006-12-07 | 2015-05-19 | Daiichi Sankyo Company, Limited | Pharmaceutical composition containing low-substituted hydroxypropyl cellulose |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI428151B (zh) * | 2006-12-07 | 2014-03-01 | Daiichi Sankyo Co Ltd | 含有甘露醇或乳糖之固形製劑 |
WO2008069262A1 (ja) * | 2006-12-07 | 2008-06-12 | Daiichi Sankyo Company, Limited | 安定性が改善されたフィルムコーティング製剤 |
WO2009098142A1 (en) | 2008-02-06 | 2009-08-13 | Helm Ag | Prasugrel salts with improved properties |
TR201005900A1 (tr) * | 2010-07-19 | 2012-02-21 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Geliştirilmiş stabiliteye sahip prasugrel granülleri. |
TR201007926A1 (tr) * | 2010-07-19 | 2012-02-21 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Prasugrel tablet formülasyonları. |
EP2409685A3 (en) * | 2010-07-19 | 2012-02-01 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally-disintegrating formulations of prasugrel |
TR201006802A1 (tr) * | 2010-08-17 | 2012-03-21 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Prasugrelin oral yolla dağılan formülasyonları. |
CZ2011872A3 (cs) | 2011-12-22 | 2013-07-03 | Zentiva, K.S. | Farmaceutická formulace prasugrelu hydrobromidu |
US8603537B2 (en) | 2012-04-02 | 2013-12-10 | Egis Pharmaceuticals Plc | Prasugrel containing quickly released stable oral pharmaceutical compositions |
EP3528790A1 (en) | 2016-10-21 | 2019-08-28 | Laboratorios Lesvi S.L. | Pharmaceutical formulations of prasugrel and processes for the preparation thereof |
WO2022192097A1 (en) * | 2021-03-06 | 2022-09-15 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02240024A (ja) * | 1989-03-13 | 1990-09-25 | Ss Pharmaceut Co Ltd | 活性型ビタミンd↓3類製剤用組成物 |
JPH0641139A (ja) | 1991-09-09 | 1994-02-15 | Sankyo Co Ltd | ヒドロピリジン誘導体 |
JPH0812582A (ja) * | 1994-06-27 | 1996-01-16 | Kowa Co | 損傷皮膚修復用粉末製剤 |
JPH08502264A (ja) * | 1992-10-06 | 1996-03-12 | ワーナー−ランバート・コンパニー | 認識障害の経口療法用新規組成物およびそのための方法 |
JPH10310586A (ja) | 1996-06-26 | 1998-11-24 | Sankyo Co Ltd | ヒドロピリジン類の新規医薬用途 |
JP2002145883A (ja) | 2000-07-06 | 2002-05-22 | Sankyo Co Ltd | ヒドロピリジン誘導体酸付加塩 |
JP2002255814A (ja) * | 2000-12-25 | 2002-09-11 | Sankyo Co Ltd | アスピリンを含有する医薬組成物 |
JP2003160500A (ja) * | 2001-11-21 | 2003-06-03 | Showa Yakuhin Kako Kk | ポピドンヨード含有組成物 |
JP2003246735A (ja) | 2001-12-21 | 2003-09-02 | Sankyo Co Ltd | ヒドロピリジン誘導体酸付加塩を含有する医薬 |
JP2004051639A (ja) | 2002-07-18 | 2004-02-19 | Sankyo Co Ltd | 動脈硬化症治療のための医薬組成物 |
WO2004098713A2 (en) | 2003-05-05 | 2004-11-18 | Eli Lilly And Company | Treating cardiovascular diseases with a compound of formula (i) (cs 747 - prasugrel; rn 150322-43-4) |
JP2006206612A (ja) * | 2004-05-27 | 2006-08-10 | Ono Pharmaceut Co Ltd | 固形製剤用組成物 |
WO2006135605A2 (en) * | 2005-06-10 | 2006-12-21 | Eli Lilly And Company | Formulation of a thienopyridine platelet aggregation inhibitor |
WO2006138317A2 (en) * | 2005-06-17 | 2006-12-28 | Eli Lilly And Company | Dosage regimen for prasugrel |
WO2007020935A1 (ja) * | 2005-08-17 | 2007-02-22 | Ono Pharmaceutical Co., Ltd. | P2y12受容体および/またはp2y14受容体ブロッカーを含有してなる疼痛治療剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9414045D0 (en) * | 1994-07-12 | 1994-08-31 | Berwind Pharma Service | Moisture barrier film coating composition, method, and coated form |
ES2364145T3 (es) * | 1996-11-15 | 2011-08-25 | Ajinomoto Co., Inc. | Composición de nateglinida en comprimidos. |
CA2374760A1 (en) * | 1999-06-18 | 2000-12-28 | Takeda Chemical Industries, Ltd. | Quickly disintegrating solid preparations |
DE60110666T2 (de) * | 2000-03-17 | 2006-02-02 | Shin-Etsu Chemical Co., Ltd. | Feste Zubereitung enthaltend niedersubstituierte Hydroxypropylcellulose und Herstellungsverfahren |
KR20090033917A (ko) * | 2000-07-06 | 2009-04-06 | 다이이찌 산쿄 가부시키가이샤 | 히드로피리딘 유도체 산부가염 |
JP2002072428A (ja) * | 2000-07-21 | 2002-03-12 | Agfa Gevaert Nv | カラー写真ハロゲン化銀材料 |
ES2292414T3 (es) * | 2000-07-27 | 2008-03-16 | Roquette Freres | Granulos a base de almidon y de lactosa. |
ES2311498T3 (es) * | 2000-12-25 | 2009-02-16 | Daiichi Sankyo Company, Limited | Composiciones medicinales que contienen aspirina. |
MXPA05000726A (es) * | 2002-07-18 | 2005-04-08 | Sankyo Co | Composicion medicinal para tratar arteriosclerosis. |
EP1656930A1 (en) * | 2004-11-10 | 2006-05-17 | Basilea Pharmaceutica AG | Stabilized freeze-dried formulation for cephalosporin derivatives |
US9034860B2 (en) * | 2006-12-07 | 2015-05-19 | Daiichi Sankyo Company, Limited | Pharmaceutical composition containing low-substituted hydroxypropyl cellulose |
TWI428151B (zh) * | 2006-12-07 | 2014-03-01 | Daiichi Sankyo Co Ltd | 含有甘露醇或乳糖之固形製劑 |
WO2008069262A1 (ja) * | 2006-12-07 | 2008-06-12 | Daiichi Sankyo Company, Limited | 安定性が改善されたフィルムコーティング製剤 |
-
2007
- 2007-12-06 CA CA2672154A patent/CA2672154C/en active Active
- 2007-12-06 WO PCT/JP2007/073548 patent/WO2008072532A1/ja active Application Filing
- 2007-12-06 EP EP07850164A patent/EP2100607A4/en not_active Ceased
- 2007-12-06 US US12/312,966 patent/US20100280064A1/en not_active Abandoned
- 2007-12-06 JP JP2008549265A patent/JPWO2008072532A1/ja active Pending
- 2007-12-06 BR BRPI0719398 patent/BRPI0719398A2/pt not_active Application Discontinuation
- 2007-12-06 CN CN2007800449061A patent/CN101600431B/zh active Active
- 2007-12-06 KR KR1020097011251A patent/KR101647842B1/ko active IP Right Grant
- 2007-12-06 TW TW096146470A patent/TWI488657B/zh active
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02240024A (ja) * | 1989-03-13 | 1990-09-25 | Ss Pharmaceut Co Ltd | 活性型ビタミンd↓3類製剤用組成物 |
JPH0641139A (ja) | 1991-09-09 | 1994-02-15 | Sankyo Co Ltd | ヒドロピリジン誘導体 |
JPH08502264A (ja) * | 1992-10-06 | 1996-03-12 | ワーナー−ランバート・コンパニー | 認識障害の経口療法用新規組成物およびそのための方法 |
JPH0812582A (ja) * | 1994-06-27 | 1996-01-16 | Kowa Co | 損傷皮膚修復用粉末製剤 |
JPH10310586A (ja) | 1996-06-26 | 1998-11-24 | Sankyo Co Ltd | ヒドロピリジン類の新規医薬用途 |
JP2002145883A (ja) | 2000-07-06 | 2002-05-22 | Sankyo Co Ltd | ヒドロピリジン誘導体酸付加塩 |
JP2002255814A (ja) * | 2000-12-25 | 2002-09-11 | Sankyo Co Ltd | アスピリンを含有する医薬組成物 |
JP2003160500A (ja) * | 2001-11-21 | 2003-06-03 | Showa Yakuhin Kako Kk | ポピドンヨード含有組成物 |
JP2003246735A (ja) | 2001-12-21 | 2003-09-02 | Sankyo Co Ltd | ヒドロピリジン誘導体酸付加塩を含有する医薬 |
JP2004051639A (ja) | 2002-07-18 | 2004-02-19 | Sankyo Co Ltd | 動脈硬化症治療のための医薬組成物 |
WO2004098713A2 (en) | 2003-05-05 | 2004-11-18 | Eli Lilly And Company | Treating cardiovascular diseases with a compound of formula (i) (cs 747 - prasugrel; rn 150322-43-4) |
JP2006206612A (ja) * | 2004-05-27 | 2006-08-10 | Ono Pharmaceut Co Ltd | 固形製剤用組成物 |
WO2006135605A2 (en) * | 2005-06-10 | 2006-12-21 | Eli Lilly And Company | Formulation of a thienopyridine platelet aggregation inhibitor |
WO2006138317A2 (en) * | 2005-06-17 | 2006-12-28 | Eli Lilly And Company | Dosage regimen for prasugrel |
WO2007020935A1 (ja) * | 2005-08-17 | 2007-02-22 | Ono Pharmaceutical Co., Ltd. | P2y12受容体および/またはp2y14受容体ブロッカーを含有してなる疼痛治療剤 |
Non-Patent Citations (4)
Title |
---|
D. CHULIA ET AL.: "Powder Technology and Pharmaceutical Process", 1 December 1993, ELSERVIER SCIENCE PUB CO |
HERBERT A. LIEBERMAN ET AL.: "Pharmaceutical Dosage Forms: Tablets", vol. 1, 1989, MARCEL DEKKER INC. |
LEON LACHMAN ET AL.: "The Theory and Practice of Industrial Pharmacy", 1986, LEA & FEBIGER |
See also references of EP2100607A4 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9034860B2 (en) | 2006-12-07 | 2015-05-19 | Daiichi Sankyo Company, Limited | Pharmaceutical composition containing low-substituted hydroxypropyl cellulose |
DE102009036646A1 (de) | 2009-08-07 | 2011-02-10 | Ratiopharm Gmbh | Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon |
WO2011015599A1 (de) | 2009-08-07 | 2011-02-10 | Ratiopharm Gmbh | Prasugrel in nicht-kristalliner form und pharmazeutische zusammensetzung davon |
WO2011052499A1 (ja) * | 2009-10-28 | 2011-05-05 | 第一三共株式会社 | 貯蔵安定性が改善された医薬組成物 |
WO2011052500A1 (ja) * | 2009-10-28 | 2011-05-05 | 第一三共株式会社 | ワックス安定製剤 |
WO2011098536A1 (en) | 2010-02-11 | 2011-08-18 | Ratiopharm Gmbh | Prasugrel in micronized, crystalline form and pharmaceutical composition thereof |
EP2360159A1 (de) | 2010-02-11 | 2011-08-24 | Ratiopharm GmbH | Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon |
EP2377520A1 (de) | 2010-03-24 | 2011-10-19 | Ratiopharm GmbH | Pharmazeutische Zusammensetzung des Prasugrels |
WO2013024663A1 (ja) * | 2011-08-12 | 2013-02-21 | 三菱瓦斯化学株式会社 | 保存安定性に優れたs-アデノシル-l-メチオニン含有組成物 |
JPWO2013024663A1 (ja) * | 2011-08-12 | 2015-03-05 | 三菱瓦斯化学株式会社 | 保存安定性に優れたs−アデノシル−l−メチオニン含有組成物 |
US9700629B2 (en) | 2011-08-12 | 2017-07-11 | Mitsubishi Gas Chemical Company, Inc. | Composition containing S-adenosyl-L-methionine with excellent storage stability |
Also Published As
Publication number | Publication date |
---|---|
KR101647842B1 (ko) | 2016-08-11 |
TWI488657B (zh) | 2015-06-21 |
EP2100607A1 (en) | 2009-09-16 |
KR20090100338A (ko) | 2009-09-23 |
CN101600431A (zh) | 2009-12-09 |
TW200831138A (en) | 2008-08-01 |
BRPI0719398A2 (pt) | 2015-03-31 |
CA2672154C (en) | 2014-11-18 |
US20100280064A1 (en) | 2010-11-04 |
CA2672154A1 (en) | 2008-06-19 |
JPWO2008072532A1 (ja) | 2010-03-25 |
CN101600431B (zh) | 2011-09-07 |
EP2100607A4 (en) | 2010-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008072532A1 (ja) | 貯蔵安定性が改善された医薬組成物 | |
JP5274261B2 (ja) | 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物 | |
TWI442947B (zh) | 安定性經改善之薄膜塗覆製劑 | |
JP5289975B2 (ja) | マンニトール又は乳糖を含有する固形製剤 | |
CA2182004C (en) | Film coated tablet of paracetamol and domperidone | |
JP5433235B2 (ja) | 固形製剤の製造方法 | |
JP6680297B2 (ja) | 経口投与用医薬組成物 | |
JP2012180280A (ja) | 貯蔵安定性が改善された固形製剤 | |
WO2003075918A1 (fr) | Comprime contenant du chlorhydrate de pilsicainide (voie humide) | |
WO2007129522A1 (ja) | 乾式製造法製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780044906.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07850164 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008549265 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007850164 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097011251 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12312966 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2672154 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: PI0719398 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090528 |